Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer

OS in the everyday clinical setting was inferior to that observed in randomized trials. Our results indicate that elderly patients and patients with moderate anemia or a history of MESCC at baseline have a greater risk of treatment-induced toxicity. Dose reductions did not compromise survival.